Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
A 40-Year-Old Woman Presenting with Encepatholopathy and Paraparesis
Neurol 101:e94-e98, AlSabah,A.,et al, 2023
Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Neurol 96:e2006-e2015, Collongues, N.,et al, 2021
CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies
Neurol 97:e1351-e1358, Zhao-Fleming,H.H.,et al, 2021
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Area Postrema Syndrome
Neurol 91:e1642-e1651, Shosha, E.,et al, 2018
A Man with Rapidly Ascending Paralysis
Neurol 89:e25-e31, Rosenberg, J.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Discriminating Long Myelitis of Neuromyelitis Optica from Sarcoidosis
Ann Neurol 79:437-447, Flanagan, E.P.,et al, 2016
Persistent Hyperthermia in a Patient with Aquaporin-4-Antibody-Positive Neuromyelitis Optica Spectrum Disorder
J Clin Neurol 12:515-516, Hsu,C-L.,et al, 2016
Treatment Outcomes with Rituximab in 100 Patients with Neuromyelitis Optica
JAMA Neurol 72:989-995, Kim, S.H.,et al, 2015
Very Late-Onset Neuromyelitis Optica Spectrum Disorder Beyond the Age of 75
J Neurol 262:1379-1384, Krumbholz, M.,et al, 2015
Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 71:1372-1378, Huh, S.Y.,et al, 2014